AXTI•November 19, 2026 at 5:41 PM UTCSemiconductors & Semiconductor Equipment

AXTI's InP backlog tops $500M, but export-permit risk still gates revenue conversion

Read source article

What happened

AXT announced that its indium phosphide (InP) backlog surpassed $500 million in Q3 2026, driven by demand from AI data center connectivity and the shift to 800G and 1.6T optical transceivers. This backlog figure is more than five times its trailing quarterly revenue of around $27 million, highlighting the magnitude of unmet demand. However, AXT's filings have repeatedly cautioned that backlog alone does not translate into revenue until wafers are produced, export permits are obtained, and shipments occur. The company faced China export controls on InP substrates since February 2025, and as of the latest 10-Q, it still had backlog without permits and could not estimate timing. While the growing backlog validates the demand thesis, investors must focus on whether the company can convert it into actual shipments and reported revenue.

Implication

Investors should treat the $500M backlog as further evidence of strong AI-driven demand for InP substrates, but they must demand hard data on shipment growth and permit approvals before upgrading the stock. The master report's WAIT rating remains appropriate because the key risk—China export permits—has not been resolved; in fact, North America revenue was only about 2% of FY2025 sales. The company's ability to ramp 6-inch capacity and deliver compliant wafers on schedule is still unproven, and Coherent's own internal InP expansion could reduce external sourcing needs over time. Until AXT reports sequential revenue growth above $22M in substrate sales and inventory stabilizes below $95M, the stock's rich valuation (market cap $2.65B vs trailing revenue ~$100M) offers little margin of safety. The news may trigger short-term momentum but does not change the fundamental risk-reward balance.

Thesis delta

The news strengthens the demand side of the thesis by confirming a massive backlog, but it does not alter the supply-side uncertainty around export permits and capacity execution. The thesis remains a WAIT because the bottleneck is not demand but the company's ability to ship compliant wafers. If AXT can demonstrate routine permit approvals and sustained shipment growth in upcoming quarters, the thesis would upgrade to a more constructive stance.

Confidence

high